JBIONASDAQHealthcare · Biotechnology

Jade Biosciences, Inc.

$23.34+6.67%(+$1.46)

TickerSpark Score

65/100

Solid

Valuation

Profitability

Growth

Health

100

Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a JBIO research report →

52-Week Range78% of range

Low $6.57

Current $23.34

High $28.00

Companyjadebiosciences.com

Jade Biosciences, Inc. is a biotechnology company focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Their lead asset, JADE-001, targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for the treatment of immunoglobulin A (IgA) nephropathy.

CEO: Tom Frohlich
IPO: 2025
Employees: 50
HQ: Waltham, MA, US

Price Chart

+202.33% · this period

Valuation

Market Cap: $761.49M
P/E: -10.40
P/S: 0.00
P/B: 4.55
EV/EBITDA: -5.29
Div Yield: 0.00%

Profitability

Gross Margin: 0.00%
Op Margin: 0.00%
Net Margin: 0.00%
ROE: -51.34%
ROIC: -44.96%

Growth & Income

Revenue: $0 · 0.00%
Net Income: $-127,410,000 · -82.99%
EPS: $-4.06 · 95.24%
Op Income: $-113,542,000
FCF YoY: -33.27%

Performance & Tape

52W High: $28.00
52W Low: $6.57
50D MA: $19.58
200D MA: $13.52
Beta: 1.52
Avg Volume: 571.04K

Get TickerSpark's AI analysis on JBIO

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime

Recent Insider Transactions

Date	Insider	Role	Type	Shares	Value
Feb 12, 26	Dahms Bradford D.	officer: Chief Financial Officer	other	226,875	$3.36M
Feb 12, 26	Dahms Bradford D.	officer: Chief Financial Officer	other	37,813	$0
Feb 12, 26	Balta Elizabeth	officer: See Remarks	other	168,750	$2.50M
Feb 12, 26	Balta Elizabeth	officer: See Remarks	other	28,125	$0
Feb 12, 26	Frohlich Tom	director, officer: Chief Executive Officer	other	472,500	$7.00M
Feb 12, 26	Frohlich Tom	director, officer: Chief Executive Officer	other	78,750	$0
Feb 12, 26	King Andrew James	officer: See Remarks	other	41,250	$0
Feb 12, 26	King Andrew James	officer: See Remarks	other	247,500	$3.67M
Oct 6, 25	Fairmount Funds Management LLC	director, 10 percent owner:	other	1,333,126	$12.18M
Oct 6, 25	Fairmount Funds Management LLC	director, 10 percent owner:	other	855,047	$85.505